Labcorp Plasma Focus™ liquid biopsy test now available

Liquid biopsy tes t for cancer patients enables oncologists to identify targeted therapies and improve care BURLINGTON, N.C. , May 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, has launched Labcorp Plasma Focus, a new liquid biopsy test enabling targeted

Labcorp and BML announce expansion of clinical laboratory testing capabilities in Japan

Advanced technology supports drug development across diseases including cancer and cerebrovascular disease

Labcorp and Providence expand strategic laboratory relationship

Patients and Providers in Oregon Region Will Gain Broader Access to Labcorp's Diagnostic Testing and Laboratory Services Labcorp and Providence Health & Services – Oregon (Providence Oregon) have entered into an agreement for Labcorp to acquire select assets of Providence Oregon's outreach

Labcorp to Webcast Its Annual Meeting of Shareholders

BURLINGTON, N.C. , May 4, 2023 /PRNewswire/ -- Labcorp  (NYSE: LH), a leading global life sciences company, today announced that its Annual Meeting of Shareholders will be webcast live on May 11 at 9:00 a.m. ET and can be viewed online on the Labcorp Investor Relations website .

Labcorp and Jefferson Health Announce Strategic Laboratory Relationship

Physicians and Patients Will Gain Access to Enhanced Laboratory Services and Advanced Diagnostic Testing Labcorp will acquire select assets of Jefferson's outreach laboratory services Jefferson will continue to own and operate their existing hospital labs for outpatient and inpatient services

Labcorp Announces 2023 First Quarter Results

Company Updates Full-Year Guidance First quarter Base Business revenue grew 10%, while total revenue and earnings were down due to COVID-19 Testing Revenue: Q1 of $3.8 billion versus $3.9 billion last year Diluted EPS: Q1 of $2.39 versus $5.23 last year Adjusted EPS: Q1 of $3.82 versus $6.11 last

Genomic landscape of patients with non-small cell lung cancer

Enhanced detection and classification of cell-free DNA alterations through matched normal analyses with PGDx elio plasma complete

Complementary use of DNA- and RNA-based NGS assays optimizes detection of clinically relevant translocations for comprehensive genomic profiling

Inhibition of murine myeloid suppressor cells increases CD8+T cell activation in vitro